Contrast-induced nephropathy: An "all or none" phenomenon?

Angiology

Volumn 66, Issue 6, 2015, Pages 508-513

  Katsiki, Niki ^a   Athyros, Vasilios G ^a   Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^b,c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

cardiovascular morbidity; chronic kidney disease; contrast induced nephropathy; mortality; prevention; statins

Indexed keywords

BIOLOGICAL MARKER; CONTRAST MEDIUM;

ARTICLE; CARDIOVASCULAR DISEASE; CONTRAST INDUCED NEPHROPATHY; DETERIORATION; EARLY DIAGNOSIS; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYDRATION; KIDNEY FUNCTION; MORBIDITY; MORTALITY; OUTPATIENT; RISK FACTOR; CHEMICALLY INDUCED; DRUG EFFECTS; KIDNEY; KIDNEY DISEASE;

CONTRAST MEDIA; HUMANS; KIDNEY; KIDNEY DISEASES;

EID: 84931036905     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319714550309     Document Type: Article

References (79)

1. Abaci O, Harmankaya O, et al. Long-term follow-up of patients at high risk for nephropathy after contrast exposure. Angiology. 2015 ; 66 ((6)). 514-518
2. Golshahi J, Nasri H, Gharipour M. Contrast-induced nephropathy; a literature review. J Nephropathol. 2014 ; 3 ((2)). 51-56
3. Stacul F, van der Molen AJ, Reimer P, et al. Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2011 ; 21 ((12)). 2527-2541
4. Harjai KJ, Raizada A, Shenoy C, et al. A comparison of contemporary definitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system. Am J Cardiol. 2008 ; 101 ((6)). 812-819
5. Kume K, Yasuoka Y, Adachi H, et al. Impact of contrast-induced acute kidney injury on outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Cardiovasc Revasc Med. 2013 ; 14 ((5)). 253-257
6. Wi J, Ko YG, Kim JS, et al. Impact of contrast-induced acute kidney injury with transient or persistent renal dysfunction on long-term outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention. Heart. 2011 ; 97 ((21)). 1753-1757
7. James MT, Samuel SM, Manning MA, et al. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: a systematic review and meta-analysis. Circ Cardiovasc Interv. 2013 ; 6 ((1)). 37-43
8. Oduncu V, Erkol A, Karabay CY, et al. Relation of the severity of contrast induced nephropathy to SYNTAX score and long term prognosis in patients treated with primary percutaneous coronary intervention. Int J Cardiol. 2013 ; 168 ((4)). 3480-3485
9. Abe M, Morimoto T, Akao M, et al. Relation of contrast-induced nephropathy to long-term mortality after percutaneous coronary intervention. Am J Cardiol. 2014 ; 114 ((3)). 362-368
10. Nemoto N, Iwasaki M, Nakanishi M, et al. Impact of continuous deterioration of kidney function 6 to 8 months after percutaneous coronary intervention for acute coronary syndrome. Am J Cardiol. 2014 ; 113 ((10)). 1647-1651
11. Caglar IM, Demir B, Caglar FN, et al. Contrast layering: late clearance of contrast dye-a novel angiographic phenomenon of early atherosclerosis. Angiology. 2015 ; 66 ((2)). 136-142
12. Toprak O. Conflicting and new risk factors for contrast induced nephropathy. J Urol. 2007 ; 178 ((6)). 2277-2283
13. Andreucci M, Solomon R, Tasanarong A. Side effects of radiographic contrast media: pathogenesis, risk factors, and prevention. Biomed Res Int. 2014 ; 2014: 741018
14. Lee J, Cho JY, Lee HJ, et al. Contrast-induced nephropathy in patients undergoing intravenous contrast-enhanced computed tomography in Korea: a multi-institutional study in 101487 patients. Korean J Radiol. 2014 ; 15 ((4)). 456-463
15. Nough H, Eghbal F, Soltani M, et al. Incidence and main determinants of contrast-induced nephropathy following coronary angiography or subsequent balloon angioplasty. Cardiorenal Med. 2013 ; 3 ((2)). 128-135
16. Moos SI, van Vemde DN, Stoker J, Bipat S. Contrast induced nephropathy in patients undergoing intravenous (IV) contrast enhanced computed tomography (CECT) and the relationship with risk factors: a meta-analysis. Eur J Radiol. 2013 ; 82 ((9)). e387 - e399
17. Pakfetrat M, Nikoo MH, Malekmakan L, et al. Comparison of risk factors for contrast-induced acute kidney injury between patients with and without diabetes. Hemodial Int. 2010 ; 14 ((4)). 387-392
18. Toprak O, Cirit M, Yesil M, et al. Metabolic syndrome as a risk factor for contrast-induced nephropathy in non-diabetic elderly patients with renal impairment. Kidney Blood Press Res. 2006 ; 29 ((1)). 2-9
19. Jaipaul N, Manalo R, Sadjadi SA, McMillan J. Obesity is not associated with contrast nephropathy. Ther Clin Risk Manag. 2010 ; 6: 213-217
20. Lucreziotti S, Centola M, Salerno-Uriarte D, et al. Female gender and contrast-induced nephropathy in primary percutaneous intervention for ST-segment elevation myocardial infarction. Int J Cardiol. 2014 ; 174 ((1)). 37-42
21. Kiski D, Stepper W, Breithardt G, Reinecke H. Impact of female gender on frequency of contrast medium-induced nephropathy: post hoc analysis of dialysis versus diuresis trial. J Womens Health (Larchmt). 2010 ; 19 ((7)). 1363-1368
22. Lüders F, Malyar N, Meyborg M, Gebauer K, Brand E, Reinecke H. Impact of peripheral arterial occlusive disease on the development of contrast medium-induced acute kidney injury. Nephron Clin Pract. 2012 ; 122 ((1-2)). 38-43
23. Barbieri L, Verdoia M, Schaffer A, et al. Elevated homocysteine and the risk of contrast-induced nephropathy: a cohort study. Angiology. 2015 ; 66 ((4)). 333-338
24. Börekçi A, Gür M, Türkoʇlu C, et al. Oxidative stress and paraoxonase 1 activity predict contrast-induced nephropathy in patients with ST-Segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Angiology. 2015 ; 66 ((4)). 339-345
25. Uçar H, Gür M, Yildirim A, et al. Increased aortic stiffness predicts contrast-induced nephropathy in patients with stable coronary artery disease undergoing percutaneous coronary intervention. Angiology. 2014 ; 65 ((9)). 806-811
26. Jian-Wei Z, Yu-Jie Z, Shu-Jun C, Qing Y, Shi-Wei Y, Bin N. Impact of preprocedural high-sensitivity C-reactive protein on contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention. Angiology. 2014 ; 65 ((5)). 402-407
27. Elbasan Z, Şahin DY, Gür M, et al. Contrast-induced nephropathy in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Angiology. 2014 ; 65 ((1)). 37-42
28. Huang SS, Huang PH, Wu TC, Chen JW, Lin SJ. Association of serum bilirubin with contrast-induced nephropathy and future cardiovascular events in patients undergoing coronary intervention. PLoS One. 2012 ; 7 ((8)). e42594
29. Kurtul A, Duran M, Yarlioglues M, et al. Association between N-Terminal pro-brain natriuretic peptide levels and contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Clin Cardiol. 2014 ; 37 ((8)). 485-492
30. Kurtul A, Yarlioglues M, Murat SN, et al. Red cell distribution width predicts contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Angiology. 2015 ; 66 ((5)). 433-440
31. Kaya A, Kaya Y, Topçu S, et al. Neutrophil-to-lymphocyte ratio predicts contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention. Angiology. 2014 ; 65 ((1)). 51-56
32. Kooiman J, Le Haen PA, Gezgin G, et al. Contrast-induced acute kidney injury and clinical outcomes after intra-arterial and intravenous contrast administration: risk comparison adjusted for patient characteristics by design. Am Heart J. 2013 ; 165 ((5)). 793-799
33. Karlsberg RP, Dohad SY, Sheng R. Iodixanol Peripheral Computed Tomographic Angiography Study Investigator Panel. Contrast medium-induced acute kidney injury: comparison of intravenous and intraarterial administration of iodinated contrast medium. J Vasc Interv Radiol. 2011 ; 22 ((8)). 1159-1165
34. Minsinger KD, Kassis HM, Block CA, Sidhu M, Brown JR. Meta-analysis of the effect of automated contrast injection devices versus manual injection and contrast volume on risk of contrast-induced nephropathy. Am J Cardiol. 2014 ; 113 ((1)). 49-53
35. Bolognese L, Falsini G, Schwenke C, et al. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] trial). Am J Cardiol. 2012 ; 109 ((1)). 67-74
36. Stratta P, Quaglia M, Airoldi A, Aime S. Structure-function relationships of iodinated contrast media and risk of nephrotoxicity. Curr Med Chem. 2012 ; 19 ((5)). 736-743
37. Biondi-Zoccai G, Lotrionte M, Thomsen HS, et al. Nephropathy after administration of iso-osmolar and low-osmolar contrast media: evidence from a network meta-analysis. Int J Cardiol. 2014 ; 172 ((2)). 375-380
38. Chicaíza-Becerra LA, García-Molina M, Gamboa Ó. Cost-effectiveness of iso- versus low-osmolality contrast media in outpatients with high risk of contrast medium-induced nephropathy. Biomedica. 2012 ; 32 ((2)). 182-188
39. Ohno I, Hayashi H, Aonuma K, et al. Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version: JSN, JRS, and JCS Joint Working Group. Clin Exp Nephrol. 2013 ; 17 ((4)). 441-479
40. Khurana R, Malik IS. Metformin: safety in cardiac patients. Heart. 2010 ; 96 ((2)). 99-102
41. Owen RJ, Hiremath S, Myers A, Fraser-Hill M, Barrett BJ. Canadian Association of radiologists consensus guidelines for the prevention of contrast-induced nephropathy: update 2012. Can Assoc Radiol J. 2014 ; 65 ((2)). 96-105
42. Celik O, Ozturk D, Akin F, et al. Association between contrast media volume-glomerular filtration rate ratio and contrast-induced acute kidney injury after primary percutaneous coronary intervention. Angiology. 2015 ; 66 ((6)). 519-524
43. Tan N, Liu Y, Zhou YL, et al. Contrast medium volume to creatinine clearance ratio: a predictor of contrast-induced nephropathy in the first 72 hours following percutaneous coronary intervention. Catheter Cardiovasc Interv. 2012 ; 79 ((1)). 70-75
44. Yoon HJ, Hur SH. Determination of safe contrast media dosage to estimated glomerular filtration rate ratios to avoid contrast-induced nephropathy after elective percutaneous coronary intervention. Korean Circ J. 2011 ; 41 ((5)). 265-271
45. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004 ; 44 ((7)). 1393-1399
46. Fu N, Li X, Yang S, et al. Risk score for the prediction of contrast-induced nephropathy in elderly patients undergoing percutaneous coronary intervention. Angiology. 2013 ; 64 ((3)). 188-194
47. Tziakas D, Chalikias G, Stakos D, et al. Validation of a new risk score to predict contrast-induced nephropathy after percutaneous coronary intervention. Am J Cardiol. 2014 ; 113 ((9)). 1487-1493
48. Raposeiras-Roubín S, Aguiar-Souto P, Barreiro-Pardal C, et al. GRACE risk score predicts contrast induced nephropathy in patients with acute coronary syndrome and normal renal function. Angiology. 2013 ; 64 ((1)). 31-39
49. Dabare D, Banihani M, Gibbs P, Grewal P. Does bicarbonate prevent contrast-induced nephropathy in cardiovascular patients undergoing contrast imaging?. Interact Cardiovasc Thorac Surg. 2013 ; 17 ((6)). 1028-1035
50. Sadat U, Walsh SR, Norden AG, Gillard JH, Boyle JR. Does oral N-acetylcysteine reduce contrast-induced renal injury in patients with peripheral arterial disease undergoing peripheral angiography? A randomized-controlled study. Angiology. 2011 ; 62 ((3)). 225-230
51. Loomba RS, Shah PH, Aggarwal S, Arora RR. Role of N-Acetylcysteine to prevent contrast-induced nephropathy: a meta-analysis [published online August 26, 2013]. Am J Ther. 2013 ;:
52. O'sullivan S, Healy DA, Moloney MC, Grace PA, Walsh SR. The role of N-acetylcysteine in the prevention of contrast-induced nephropathy in patients undergoing peripheral angiography: a structured review and meta-analysis. Angiology. 2013 ; 64 ((8)). 576-582
53. Sun Z, Fu Q, Cao L, Jin W, Cheng L, Li Z. Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials. PLoS One. 2013 ; 8 ((1)). e55124
54. Berwanger O, Cavalcanti AB, Sousa AM, et al. Acetylcysteine for contrast-induced nephropathy trial investigators. Acetylcysteine for the prevention of renal outcomes in patients with diabetes mellitus undergoing coronary and peripheral vascular angiography: a substudy of the acetylcysteine for contrast-induced nephropathy trial. Circ Cardiovasc Interv. 2013 ; 6 ((2)). 139-145
55. Santana-Santos E, Gowdak LH, Gaiotto FA, et al. High dose of N-acetylcystein prevents acute kidney injury in chronic kidney disease patients undergoing myocardial revascularization. Ann Thorac Surg. 2014 ; 97 ((5)). 1617-1623
56. Barbieri L, Verdoia M, Schaffer A, Nardin M, Marino P, De Luca G. The role of statins in the prevention of contrast induced nephropathy: a meta-analysis of 8 randomized trials [published online April 6, 2014]. J Thromb Thrombolysis. 2014 ;:
57. Gandhi S, Mosleh W, Abdel-Qadir H, Farkouh ME. Statins and contrast-induced acute kidney injury with coronary angiography: systematic review and meta-analysis [published online May 19, 2014]. Am J Med. 2014 ;:
58. Xie H, Ye Y, Shan G, et al. Effect of statins in preventing contrast-induced nephropathy: an updated meta-analysis [published online July 17, 2014]. Coron Artery Dis. 2014 ;:
59. Mikhailidis DP, Athyros VG. Acute kidney injury: short-term statin therapy for prevention of contrast-induced AKI. Nat Rev Nephrol. 2014 ; 10 ((1)). 8-9
60. Nasiri-Toosi Z, Dashti-Khavidaki S, Khalili H, Lessan-Pezeshki M. A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity. Eur J Clin Pharmacol. 2013 ; 69 ((5)). 1057-1073
61. Yavari V, Ostovan MA, Kojuri J, et al. The preventive effect of pentoxifylline on contrast-induced nephropathy: a randomized clinical trial. Int Urol Nephrol. 2014 ; 46 ((1)). 41-46
62. Firouzi A, Eshraghi A, Shakerian F, et al. Efficacy of pentoxifylline in prevention of contrast-induced nephropathy in angioplasty patients. Int Urol Nephrol. 2012 ; 44 ((4)). 1145-1149
63. Yang B, Xu J, Xu F, et al. Intravascular administration of mannitol for acute kidney injury prevention: a systematic review and meta-analysis. PLoS One. 2014 ; 9 ((1)). e85029
64. McCullough PA, Sandberg KR. Epidemiology of contrast induced nephropathy. Rev Cardiovasc Med. 2003 ; 4 ((suppl 5)). 53-59
65. Alharazy SM, Kong N, Saidin R, et al. Serum neutrophil gelatinase-associated lipocalin and cystatin C are early biomarkers of contrast-induced nephropathy after coronary angiography in patients with chronic kidney disease. Angiology. 2014 ; 65 ((5)). 436-442
66. Alharazy SM, Kong N, Saidin R, et al. Neutrophil gelatinase-associated lipocalin as an early marker of contrast-induced nephropathy after coronary angiography. Angiology. 2014 ; 65 ((3)). 216-223
67. Shaker OG, El-Shehaby A, El-Khatib M. Early diagnostic markers for contrast nephropathy in patients undergoing coronary angiography. Angiology. 2010 ; 61 ((8)). 731-736
68. Filiopoulos V, Biblaki D, Vlassopoulos D. Neutrophil gelatinase-associated lipocalin (NGAL): a promising biomarker of contrast-induced nephropathy after computed tomography. Ren Fail. 2014 ; 36 ((6)). 979-986
69. Ebru AE, Kilic A, Korkmaz FS, et al. Is cystatin-C superior to creatinine in the early diagnosis of contrast-induced nephropathy?: a potential new biomarker for an old complication. J Postgrad Med. 2014 ; 60 ((2)). 135-140
70. Ishibashi Y, Yamauchi M, Musha H, Mikami T, Kawasaki K, Miyake F. Impact of contrast-induced nephropathy and cardiovascular events by serum cystatin C in renal insufficiency patients undergoing cardiac catheterization. Angiology. 2010 ; 61 ((8)). 724-730
71. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009 ; 54 ((6)). 1012-1024
72. Alnaeb ME, Youssef F, Mikhailidis DP, Hamilton G. Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease. Angiology. 2006 ; 57 ((1)). 65-71
73. Quintavalle C, Fiore D, De Micco F, et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation. 2012 ; 126 ((25)). 3008-3016
74. Molnar AO, Parikh CR, Coca SG, et al. Association between preoperative statin use and acute kidney injury biomarkers in cardiac surgical procedures. Ann Thorac Surg. 2014 ; 97 ((6)). 2081-2087
75. Fassett RG, Robertson IK, Ball MJ, Geraghty DP, Cardinal JW, Coombes JS. Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post hoc analysis of the LORD trial. Nephrol Dial Transplant. 2012 ; 27 ((1)). 182-189
76. Semerci T, Cuhadar S, Akçay FA, et al. Comparing the renal safety of isoosmolar versus low-osmolar contrast medium by renal biomarkers N-acetyl-β-D-glucosaminidase and endothelin. Angiology. 2014 ; 65 ((2)). 108-112
77. Kougias P, Sharath S, Barshes NR, et al. Impact of cumulative intravascular contrast exposure on renal function in patients with occlusive and aneurysmal vascular disease. J Vasc Surg. 2014 ; 59 ((6)). 1644-1650
78. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent?. Curr Vasc Pharmacol. 2012 ; 10 ((3)). 374-377
79. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Stage of chronic kidney disease and severity of coronary heart disease manifestation. Expert Opin Pharmacother. 2012 ; 13 (4). 457-460